IntoCell, Inc. (287840.KQ) — Stock Score Summary

IntoCell, Inc. (287840.KQ) has a MoatMap StockRank of 4/100 based on Quality (27/100), Value (34/100), and Momentum (18/100) factor scores. The current signal is STRONG SELL.

IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates.

Key Financial Metrics

Price$15.60
Market Cap$227M
Price/Book14.22
Return on Equity-89.3%
Return on Invested Capital-27.2%
Debt/Equity48.11
Gross Margin99.8%
Operating Margin-1255.8%
Revenue Growth157.5%
Free Cash Flow$-3K

IntoCell, Inc. operates in the Biotechnology industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is IntoCell, Inc.’s (287840.KQ) StockRank?
MoatMap’s StockRank for IntoCell, Inc. (287840.KQ) is 4/100, with a Strong Sell signal. It is a composite of Quality (27), Value (34), and Momentum (18) factor ranks across MoatMap’s 19,000+ stock universe.
Does IntoCell, Inc. have an economic moat?
IntoCell, Inc. (287840.KQ) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is IntoCell, Inc. a buy, hold, or sell?
MoatMap’s current signal for IntoCell, Inc. (287840.KQ) is Strong Sell, based on a StockRank of 4/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is IntoCell, Inc. in?
IntoCell, Inc. (287840.KQ) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).
Browse all ranked stocks287840.KQ deep dive reportAI ChampionsHow we score stocksSense-check another stock